Catalyst OrthoScience gets FDA 510(k) Clearance of Archer® Patient-Specific Instrumentation for Shoulder Arthroplasty

Catalyst OrthoScience gets FDA 510(k) Clearance of Archer® Patient-Specific Instrumentation for Shoulder Arthroplasty

MedTech Intelligence – Read More

MTI Newswire

Press Release: MTI Staff was not involved in writing this content


NAPLES, Fla., Feb. 25, 2026 – Catalyst OrthoScience Inc. (“Catalyst”), a private medical technology company redefining shoulder arthroplasty through simplified, surgeon-focused innovation, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its Archer® Patient-Specific Instrumentation (PSI). Licensed in partnership with 3D-Side, Archer PSI is a full suite of humeral and glenoid guides tailored to the patient’s anatomy that allow orthopedic surgeons to execute their 3D preoperative plans intraoperatively with greater precision, consistency, and confidence. Catalyst is one of the only companies to offer patient-specific guides for both the glenoid and humerus.

Used in combination with the Archer® 3D Planning Software, Archer PSI enhances preoperative planning accuracy and supports intraoperative efficiency. Archer PSI is indicated for anatomic and reverse procedures, enabling surgeons to personalize humeral and glenoid implant positioning while maintaining a streamlined surgical workflow.

“As the demand for enabling technologies continues to build, the Archer PSI system is yet another milestone in our commitment to delivering meaningful clinical and operational value to surgeons,” said Ephraim Akyuz, PhD, chief technology officer at Catalyst. “The addition of PSI to the Archer 3D planning system allows surgeons to now execute more accurately to their pre-operative plans while reducing the number of procedural steps and saving valuable operative time.”

Catalyst has initiated a limited market release (LMR) of Archer PSI with select surgeon partners, including use of Archer PSI in anatomic and reverse cases. Insights gathered during LMR will help guide final product optimization ahead of a broader commercial launch.

“Archer PSI integrates seamlessly into my surgical workflow and minimizes the risk of improper implant positioning,” said Dr. Matthew Kippe, a participating LMR surgeon / one of the Archer design surgeons. “The ability to plan cases in advance and execute with patient-specific guides, tailored to each person’s anatomy is extremely beneficial, especially in complex anatomy, and I look forward to contributing feedback as Catalyst prepares for full commercial release.”

View original Press Release

The post Catalyst OrthoScience gets FDA 510(k) Clearance of Archer® Patient-Specific Instrumentation for Shoulder Arthroplasty appeared first on MedTech Intelligence.

 

FDA Approval for BIOTRONIK Solia CSP S Pacing Lead For LBBAP

FDA Approval for BIOTRONIK Solia CSP S Pacing Lead For LBBAP

Smith+Nephew signs distribution agreement with SI-BONE

Smith+Nephew signs distribution agreement with SI-BONE